drugset / Trial / NCT05678283

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

NCT05678283

Phase 1 Withdrawn Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the absorption, metabolism, and elimination of CC-90010 and its metabolites following a single oral dose of radiolabeled CC-90010 in participants with advanced solid tumors.

Timeline

Start
2023-01-09
Primary completion
2024-04-29
Completion
2024-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Trotabresib Small molecule Oral

Indications